
    
      To assess the safety and efficacy of Adipose-Derived Regenerative Cells (ADRCs) delivered via
      an intramyocardial route in the treatment of chronic ischemic heart disease in patients who
      are not eligible for percutaneous or surgical revascularization.
    
  